Response to Comments: MolDX: Minimal Residual Disease Testing for Colorectal Cancer

This document records the response to public comments on the MolDX Local Coverage Determination L38431 for Minimal Residual Disease (MRD) testing in colorectal cancer. It documents the comment period (09/26/2019–11/10/2019), the notice period beginning 09/03/2020, the effective date 10/18/2020, and a revision to the LCD title to remove the vendor-specific name.